BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Empagliflozin

empagliflozin [Supplementary Concept] structure in first source

998+ PubMed studies analyzed · 420 RCTs · Evidence Score: 73.3

Research Domains

Empagliflozin has been studied across 11 research domains including 🔥 Metabolic, ❤️ Cardiovascular, 🫘 Kidney, 🧬 Hormones, 😴 Sleep. The primary research focus is 🔥 Metabolic with 93% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Empagliflozin, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

dapagliflozin
2 shared targets
phlorizin
2 shared targets
phlorhizin
2 shared targets
kurarinone
2 shared targets
sophoraflavanone
2 shared targets
Canagliflozin
2 shared targets
phloretin
2 shared targets
pulsatilla
2 shared targets
Rubia
2 shared targets
Foeniculum
2 shared targets
Loading evidence profile...

This evidence profile for Empagliflozin is generated deterministically from 998 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.